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A B S T R A C T
Accumulating evidence suggests that anthocyanins play an important role in the cardioprotective effects asso-
ciated with consumption of anthocyanin-rich foods. These benefits may partly be attributed to their effects on
platelets, significant contributors to cardiovascular disease development. This study aimed to investigate the
impact of physiologically relevant concentrations of anthocyanins and their metabolites on platelet activation
and platelet-leukocyte aggregation.
Whole blood from seven healthy volunteers was treated with anthocyanins: cyanidin-3-arabinoside, cyanidin-
3-glucoside, cyanidin-3-galactoside, delphinidin-3-glucoside and peonidin-3-glucoside at 0.1 μM concentration
or gut metabolites: 4-hydroxybenzaldehyde, protocatechuic, vanillic, ferulic and hippuric acids at 0.5 μM,
0.2 μM, 2 μM, 1 μM, 2 μM concentration, respectively. Markers of adenosine diphosphate-induced platelet acti-
vation (P-selectin and GPIIb-IIIa expression) and platelet-monocyte and platelet-neutrophil aggregation were
analyzed using flow cytometry.
Cyanidin-3-arabinoside, delphinidin-3-glucoside, and peonidin-3-glucoside decreased agonist-induced P-se-
lectin expression, while cyanidin-3-galactoside and cyanidin-3-arabinoside reduced platelet-neutrophil ag-
gregation. Hippuric and protocatechuic acids inhibited P-selectin expression, ferulic acid reduced platelet-
monocyte aggregation, while 4-hydroxybenzaldehyde affected P-selectin expression, platelet-neutrophil and
monocyte aggregation. Only cyanidin-3-glucoside and protocatechuic acid decreased GPIIb-IIIa expression.
These results demonstrate the bioactivity of anthocyanins and their gut metabolites at physiologically re-
levant concentrations on platelet function and interaction with leukocytes, presenting mechanisms by which
they contribute to the beneficial effects of habitual consumption of anthocyanin-rich foods on cardiovascular
health.
1. Introduction
Cardiovascular diseases (CVD), representing a group of heart and
blood vessel disorders, are the number one cause of mortality world-
wide, with atherosclerosis as the most important underlying pathologic
process of their development [1]. Atherosclerosis is a chronic in-
flammatory condition characterized by changes in vascular en-
dothelium that promote the adhesion of circulating leukocytes and their
transendothelial migration. These processes further lead to the
formation of atherosclerotic lesions composed of lipids, cellular and
fibrous elements accumulated in the blood vessel wall [2]. Platelets,
cellular fragments derived from bone marrow megakaryocytes, also
contribute to the development of atherosclerosis by their activation and
subsequent interactions with leukocytes (monocytes and neutrophils)
and endothelial cells. Platelets communicate with these cells either
directly via adhesion molecules such as P-selectin and GPIIb-IIIa pre-
sent on the surface of activated platelets or indirectly through various
platelet-derived inflammatory mediators that are released upon their
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activation. These interactions promote the adhesion and transmigration
of leukocytes, amplifying the inflammatory responses and accelerating
atherosclerosis [3,4]. The increased platelet activation and formation of
platelet-leukocyte aggregates have been reported in people with hy-
pertension [5], diabetes [6], ischemic heart disease [7,8] and stroke
[9]. Thus, they are more and more regarded as a biomarker of CVD risk
and a target for the prevention and treatment of CVD [3].
Accumulating evidence suggests that anthocyanins, phenolic phy-
tochemicals abundantly found in berry fruits and derived beverages,
play a protective role against CVD [10–15]. The observed cardiopro-
tective effects have been associated primarily with the ability of these
compounds to improve endothelial function and decrease inflammation
[16]. However, these cardiovascular benefits may be, at least partly,
attributed to the effect of anthocyanins on platelet function. Several
dietary intervention studies with anthocyanin-rich foods or extracts
support this hypothesis by reporting reduced platelet granule secretion
[17,18] or ex vivo agonist-induced platelet activation and aggregation
[19–24] in healthy volunteers or subjects at increased CVD risk. Fur-
thermore, decreased platelet hyperactivity was observed in a few an-
imal studies with mice fed a high-fat diet enriched with anthocyanin-
based extracts or pure compounds [25,26]. Data from in vitro studies
have also demonstrated the beneficial effects of anthocyanins on pla-
telet function [18,27–31]. However, most of these in vitro studies did
not take into account the absorption, distribution, metabolism, and
excretion of anthocyanins in the body. It is now well accepted that
besides the intact anthocyanin forms (glycosides), detectable in the
bloodstream at around 100 nM concentrations following the consump-
tion of anthocyanin-rich foods [32,33], a number of anthocyanin gut
metabolites such as protocatechuic, vanillic and ferulic acids also ap-
pear in circulation at low micromolar concentrations [33,34]. However,
the available in vitro studies have mostly used parent forms, rather than
circulating metabolites, at high supra-physiological levels (up to
50 μM), producing results that lack physiological relevance. Therefore,
the reliable in vitro evidence of anthocyanins' effect on platelet function
to support the results reported in vivo are still scarce.
We have previously shown that exposure of endothelial cells to
anthocyanins and their metabolites at physiologically-relevant condi-
tions can reduce the adhesion of monocytes to activated endothelial
cells, the initial step in atherosclerosis development [35]. The aim of
this study was to investigate whether the physiological levels of these
compounds can also affect platelet activation and platelet-leukocyte
aggregation.
2. Materials and methods
2.1. Chemicals and reagents
Anthocyanins: cyanidin-3-glucoside (cy-3-glc), cyanidin-3-galacto-
side (cy-3-gal), cyanidin-3-arabinoside (cy-3-arab), delphinidin-3-glu-
coside (del-3-glc) and peonidin-3-glucoside (pn-3-glc) were purchased
from Extrasynthese (Genay, France), while metabolites: vanillic acid,
protocatechuic acid (PCA), hippuric acid, ferulic acid, 4-hydro-
xybenzaldehyde (4-HBAL) were all from Sigma-Aldrich (Saint-Quentin
Fallavier, France). Anthocyanins were dissolved in 70% ethanol with
1% hydrochloric acid (HCl) and their metabolites in 70% ethanol, to
reach 10mM and 20mM concentrations of the stock solutions, re-
spectively, and kept at −80 °C until use.
Adenosine diphosphate (ADP), ethanol, HCl, HEPES, sodium
chloride (NaCl), potassium chloride (KCl), magnesium chloride
(MgCl2), sodium bicarbonate (NaHCO3), disodium phosphate
(Na2HPO4), bovine serum albumin (BSA) and glucose were obtained
from Sigma-Aldrich (Saint-Quentin Fallavier, France). Monoclonal an-
tibodies anti-CD61 conjugated to peridinin chlorophyll protein (PerCP),
anti-CD62P conjugated to phycoerythrin (PE), PAC1 (anti-GPIIb-IIIa)
conjugated to fluorescein isothiocyanate (FITC), anti-CD61 conjugated
to FITC, anti-CD11b conjugated to PE, anti-CD14 conjugated to PerCP,
cell fix solution and FACS lysing solution were all from Becton
Dickinson (Franklin Lakes, USA).
2.2. Volunteers and blood collection
Seven apparently healthy, non-smoking male volunteers, from 28 to
34 years old were recruited. To minimize the effect of bioactive com-
pounds from the background diet on platelet function, volunteers were
requested to abstain from the consumption of alcohol, anthocyanin-rich
berry fruits, and derived products as well as from the frequently con-
sumed polyphenol-rich beverages like coffee and tea for 72 h prior to
blood collection. On a study day, the whole blood samples were col-
lected after an overnight fast and at least 20min of seated rest, ac-
cording to the standardized protocols for blood sampling in platelet
analysis [36,37]. Blood samples were collected by venipuncture
without the tourniquet in tubes containing sodium citrate (3.2%) as an
anticoagulant (BD Diagnostics, Franklin Lakes, USA) and used im-
mediately for the investigations of platelet function. Additional blood
samples were collected into serum tubes and tubes containing K2EDTA
as an anticoagulant to evaluate biochemical and hematological para-
meters, respectively. Biochemical analyses were performed using the
Cobas c111 clinical chemistry analyzer (Roche Diagnostics, Basel,
Switzerland) and Roche's diagnostic kits according to the manufac-
turer's instructions. Hematological parameters were measured with the
ABX micros 60 hematology analyzer (Horiba, Kyoto, Japan). The study
was approved by the Ethical Committee of the University Hospital
Medical Center Zemun (ref. no. 2125), and all volunteers signed the
informed consent form.
2.3. Whole blood treatments
Immediately after the collection, the whole blood samples were
incubated with anthocyanins or their metabolites for 10min at 37 °C.
All of the anthocyanins were examined at the final concentration of
0.1 μM, 4-HBAL at 0.5 μM, PCA at 0.2. μM, hippuric acid at 2 μM, ferulic
at 1 μM and vanillic at 2 μM concentration. The tested concentrations
were selected as closest to the circulating plasma levels of the in-
vestigated compounds previously reported in the studies of anthocya-
nins' bioavailability in humans [33,34]. These concentrations corre-
spond to intake of 500mg of single oral dose of cy-3-glc [33]. According
to Phenol-Explorer database (http://phenol-explorer.eu/) that provides
mean polyphenol content in plant-foods it could be assumed that these
concentrations could be achieved by consumption of around 40 g of raw
black elderberries or 260 g of blackberries.
Starting from the stock solutions, compounds were diluted in
HEPES-Tyrode's buffer (HTB) (10mM HEPES, 137mM NaCl, 2.8 mM
KCl, 1 mMMgCl2, 12mM NaHCO3, 0.04mM Na2HPO4, 5.5mM glucose,
0.35% (w/v) BSA, pH 7.4) and added to blood samples to obtain the
desired working concentrations. The whole blood samples treated with
vehicles 70% ethanol/1% HCl or 70% ethanolin matched concentration
were used as the control for the anthocyanins and their metabolites,
respectively. Platelet activation was not affected by these controls.
2.4. Determination of platelet activation and their aggregation with
leukocytes
Platelet activation and aggregation with leukocytes were measured
by whole-blood flow cytometry according to previously published
protocols with slight modifications [36,37]. Platelet activation was
evaluated based on the expression of surface antigens P-selectin and
GPIIb-IIIa, used as markers of platelet activation. Treated and control
blood samples were diluted in HTB (dilution 1:10), stimulated with a
suboptimal, 0.5 μM concentration of ADP as platelet agonist and in-
cubated with anti-CD62-PE, PAC1-FITC and anti-CD61-PerCP anti-
bodies for 20min at room temperature in the dark. An additional
sample of diluted and labeled control blood was incubated without the
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addition of ADP to monitor the extracorporeal platelet activation.
Subsequently, samples were fixed with the cell fix solution for 15min at
room temperature in the dark and analyzed using a FACS Calibur flow
cytometer and Cell Quest software, version 6.0. (Becton Dickinson,
Franklin Lakes, USA). Results were expressed both as the percentage
and mean fluorescence intensity (MFI) of P-selectin and GPIIb-IIIa po-
sitive platelets in the total number of collected platelets (20000). The
first parameter corresponded to the percentage of activated cells in the
total population of platelets and the latter is considered an indirect
measure of the average density of P-selectin or GPIIb-IIIa on activated
platelets.
Platelet-monocyte and platelet-neutrophil aggregation were as-
sessed in the whole blood samples (treated and control ones) stimulated
with 0.5 μM ADP and incubated with anti-CD61-FITC, anti-CD11b-PE,
and anti-CD14-PerCP antibodies for 15min at room temperature in the
dark. Additional control blood sample was incubated without ADP
addition and served as a negative control. Samples were subsequently
treated with FACS lysing solution for 12min, washed twice in HTB,
fixed with the cell fix solution and analyzed. The results were expressed
as a percentage of aggregates in the total population of monocytes
(1000) and neutrophils (10000).
2.5. Statistical analysis
SPSS software, version 20.0. (SPSS, Chicago, USA) was used for the
statistical analysis of data. Normality of the data was tested and con-
firmed by Shapiro-Wilk test. The values of platelet activation and ag-
gregation parameters in the samples incubated with anthocyanins or
metabolites and activated with 0.5 μM ADP were compared with the
values in vehicle-treated 0.5 μM ADP-activated samples, using paired
samples t-test. The p < 0.05 was considered as significant. All figures
were created using in Prism software, version 7a (GraphPad, La Jolla,
USA).
3. Results
3.1. Characteristics of volunteers
The hematological and biochemical profiles of the volunteers were
within normal reference ranges (Table 1). Values of systolic and dia-
stolic blood pressures were within the optimal and normal intervals
established by the European Society of Hypertension and the European
Society of Cardiology [38].
3.2. Effect of anthocyanins on markers of platelet activation
The effect of tested compounds on ADP-induced platelet activation
was examined based on their impact on two activation markers P-se-
lectin and GPIIb-IIIa, assessed as a percentage of activated cells in the
total population of platelets and as a density of these receptors on the
surface of activated platelets (MFI).
Pre-incubation of whole blood with 0.1 μM cy-3-arab significantly
affected ADP-induced platelet activation, reducing the percentage of P-
selectin positive platelets by 10.2% and P-selectin receptor density by
7.7%, compared to ADP-treated control (Fig. 1 A, B). On the contrary,
cy-3-glc significantly lowered the density of GPIIb-IIIa receptor on ac-
tivated platelets by 4.8% (Fig. 1D), while cy-3-gal did not significantly
affect any of the investigated activation markers (Fig. 1). Pre-exposure
to del-3-glc significantly attenuated the percentage of P-selectin posi-
tive platelets and the density of this receptor on activated platelets by
10.8% and 7.5%, respectively (Fig. 1A and B) while not affecting GPIIb-
IIIa. A similar effect was observed for pn-3-glc, which significantly re-
duced the percentage of P-selectin positive platelets by 10.8% (Fig. 1).
3.3. Impact of anthocyanin gut metabolites on markers of platelet activation
Pre-exposure of whole blood with 4-HBAL at 0.5 μM concentration,
significantly reduced the percentage of P-selectin positive platelets by
6.9% (Fig. 2A). On the contrary, the pre-incubation with 0.2 μM PCA
affected both investigated markers of platelet activation. PCA sig-
nificantly lowered the percentage of P-selectin and GPIIb-IIIa positive
cells by 5.9% and 3.3% respectively, as well as decreased the density of
GPIIb-IIIa on activated platelets by 5.9%, compared to ADP-treated
control (Fig. 2A, C, D). Hippuric acid, tested at 2 μM concentration,
significantly attenuated the percentage of P-selectin positive cells by
4.3% compared to control (Fig. 2A), while both ferulic and vanillic
acids failed to significantly decrease any of the investigated markers of
platelet activation (Fig. 2).
3.4. Impact of anthocyanins on platelet aggregation with leukocytes
The effects of tested compounds on ADP-induced platelet-leukocyte
aggregation were evaluated based on their impact on the percentage of
platelet-neutrophil and platelet-monocyte aggregates.
A significant decrease in platelet-neutrophil aggregation by 15.2%
and no effect on platelet-monocyte aggregation was observed upon
incubation of whole blood with 0.1 μM cy-3-arab (Fig. 3). Similarly, cy-
3-gal significantly reduced platelet-neutrophil aggregation by 19.6%,
while cy-3-glc, pn-3-glc and del-3-glc did not significantly affect neither
platelet-neutrophil nor platelet-monocyte aggregate formation.
3.5. Effect of anthocyanin gut metabolites on platelet aggregation with
leukocytes
Pre-incubation of whole blood with 0.5 μM 4-HBAL significantly
affected ADP-induced platelet-leukocyte aggregation, decreasing the
number of platelet-neutrophil and platelet-monocyte aggregates by
14.8% and 10%, respectively, compared to ADP-treated control (Fig. 4).
Ferulic acid, tested at 1 μM level, significantly lowered the formation of
platelet-monocyte aggregates by 11.4% and showed no effect on
Table 1
Characteristics of volunteers.
Characteristics of volunteers Valuesa
Age (years) 30.00 ± 2.40
Height (cm) 185.00 ± 7.00
Body weight (kg) 86.04 ± 8.80
Waist circumference (cm) 89.57 ± 6.19
Systolic blood pressure (mmHg) 119.29 ± 8.48
Diastolic blood pressure (mmHg) 68.07 ± 4.79
HGB (g/l) 140.07 ± 9.99
HCT (l/l) 0.44 ± 0.04
RBC (x 1012/l) 5.22 ± 0.42
WBC (x 109/l) 5.79 ± 0.72
PLT (x 109/l) 195.21 ± 11.81
PCT (x 10−2 l/l) 0.14 ± 0.01
MPV (fl) 7.46 ± 0.81
Total cholesterol (mmol/L) 5.02 ± 1.11
LDL-cholesterol (mmol/L) 3.33 ± 1.09
HDL-cholesterol (mmol/L) 1.56 ± 0.25
Triglycerides (mmol/L) 0.80 ± 0.31
Glucose (mmol/L) 5.04 ± 0.34
Iron (μmol/L) 20.90 ± 2.06
Urea (μmol/L) 5.31 ± 1.23
Uric acid (μmol/L) 350.29 ± 36.23
Creatinine (μmol/L) 103.59 ± 11.70
ALT (U/L) 21.67 ± 7.78
AST (U/L) 26.27 ± 5.07
a Results are expressed as mean ± SD, n= 7. HGB- Hemoglobin, HCT-
Hematocrit, RBC-Red blood cells, WBC-White blood cells, PLT-Platelet Count, PCT-
Plateletcrit, MPV-Mean platelet volume, LDL-Low-density lipoprotein, HDL-High-
density lipoprotein, ALT-Alanine transaminase, AST-Aspartate transaminase.
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aggregation of platelets with neutrophils. Finally, 0.2 μM PCA, 2 μM
hippuric acid and 2 μM vanillic acid exhibited no significant effect on
both the platelet-neutrophil and platelet-monocyte aggregation (Fig. 4).
4. Discussion
An increasing amount of evidence supports the beneficial role of
dietary anthocyanins against CVD. Findings from recent nutritional
intervention studies with anthocyanin-rich foods or extracts suggest
that these compounds could exert their cardioprotective effects through
modulations of platelet function by reducing the platelet activation and
aggregation with leukocytes [21–24]. These processes contribute to
atherosclerotic plaque formation in the blood vessel wall, playing a
critical role in the development of atherosclerosis, a chronic in-
flammatory condition that precedes CVD. In the present work, we
showed the potency of several anthocyanins and their metabolites,
detectable in the circulation following the consumption of anthocyanin-
rich sources, to decrease platelet activation ex vivo. Furthermore, for the
first time, we reported the capacity of these compounds to reduce
platelet-leukocyte aggregation.
Anthocyanins evaluated in this study are abundant in various plant-
foods, especially berries, some vegetables and fruit-derived products,
presenting the important constituents of the human diet. All five tested
anthocyanins are present in blueberries and bilberries that are among
the most frequently consumed anthocyanin sources [39]. Upon the in-
gestion, anthocyanins from these foods rapidly appear in circulation in
their intact form, but also undergo extensive metabolism, with a sig-
nificant contribution of gut microbiota. The metabolites used in this
work were previously detected in the circulation following the intake of
different anthocyanin-rich foods [32,34,40]. Additionally, a recent
human feeding study with isotope-labeled cy-3-glc confirmed the pre-
sence of these metabolites, as products of anthocyanin degradation,
formed in the small intestine and colon [33]. The selected compounds
were tested at concentrations that match their circulating plasma levels
after the consumption of anthocyanin-rich sources [32,33], to ensure
the physiological relevance of our results.
The effects on platelet function were determined by quantifying
cell-surface expression of platelet activation markers P-selectin and
GPIIb-IIIa, as well as platelet-neutrophil and monocyte aggregates, in
response to ADP as platelet agonist using the whole blood flow
Fig. 1. The impact of 0.1 μM concentration of anthocyanins on platelet activation examined as A) percentage of P-selectin positive platelets, B) P-selectin density on platelets (MFI), C)
percentage of GPIIb-IIIa positive platelets and D) GPIIb-IIIa density on platelets (MFI) in response to suboptimal levels of ADP. The results are expressed as change (%) of the value for
each of the measured parameters in the anthocyanin-treated, ADP-activated samples compared to control (vehicle-treated, ADP-activated samples). Data are represented as mean ± SD,
n = 7. *p < 0.05, **p < 0.01.
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cytometry. P-selectin is an adhesion molecule present on the membrane
of platelet α-granules that is translocated to the surface only upon
platelet activation. Binding of surface-expressed P-selectin to its ligand
P-selectin glycoprotein ligand-1 on the leukocyte surface, initiates
platelet aggregation with these cells [41], playing the significant role in
atherosclerosis development. Additionally, platelet activation results in
conformational activation of GPIIb-IIIa, a fibrinogen receptor that
mediates platelet aggregation with other platelets but also contributes
to their aggregation with leukocytes [3].
The results of our experiments revealed that with the exception of
vanillic acid, both anthocyanins and their gut metabolites had a sig-
nificant effect on at least one of the investigated parameters, i.e. platelet
activation or aggregation in response to agonist. However, the observed
effects varied between the compounds. Regarding the effects of an-
thocyanins, cy-3-arab was the most effective in modulating platelet
function, as it decreased the number of P-selectin positive platelets and
the density of this receptor on activated platelets, which was reflected
in a significant reduction of platelet aggregation with neutrophils. On
the other hand, del-3-glc, pn-3-glc and cy-3-glc affected platelet acti-
vation by shown modulation of P-selectin or GPIIb-IIIa expression,
while cy-3-gal affected only platelet-neutrophil aggregation. The ob-
served differences in the effect of these compounds could be explained
by the type of sugar attached to the C-ring of anthocyanin backbone,
and suggest that the presence of arabinose results in a higher impact on
platelet function.
Among tested metabolites, 4-HBAL was the most effective, attenu-
ating both platelet activation and aggregation. It displayed the in-
hibitory effect on P-selectin surface expression accompanied by a re-
duction in both platelet-neutrophil and monocyte aggregates formation.
It is noteworthy that in our previous study, aimed to investigate the
impact of pre-exposure of endothelial cells to anthocyanins and their
metabolites on monocytes adhesion to activated endothelial cells, 4-
Fig. 2. The effect of anthocyanin metabolites on the markers of platelet activation: A) percentage of P-selectin positive platelets, B) P-selectin density on platelets (MFI), C) percentage of
GPIIb-IIIa positive platelets and D) GPIIb-IIIa density on platelets (MFI) in response to suboptimal levels of ADP. The tested concentrations were as follows: 0.5 μM for 4-HBAL, 0.2 μM for
PCA, 2 μM for hippuric acid, 1 μM for ferulic acid and 2 μM concentration for vanillic acid. The results are expressed as change (%) of the value for each of the measured parameters in the
anthocyanin-treated, ADP-activated samples compared to control (vehicle-treated, ADP-activated samples). Data are represented as mean ± SD, n = 7. *p < 0.05, **p < 0.01.
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HBAL was the only tested compound with no effect [35]. These ob-
servations suggest that by targeting platelets and not endothelial cells,
4-HBAL still has the potential to modulate leukocyte-endothelial cell
interactions, exerting a protective effect against atherosclerosis devel-
opment.
Following the ingestion of anthocyanin-rich sources, anthocyanin
gut metabolites appear later and are present in the circulation sig-
nificantly longer than their parent-forms (up to 48 h) [33,34]. There-
fore, the shown effects of 4-HBAL, PCA, ferulic and hippuric acids
suggest that the beneficial, anti-platelet effects associated with the
habitual consumption of anthocyanin-rich foods could be a result of
combined action of anthocyanins and their metabolites on platelet
function, the effect that could last over a prolonged period post-con-
sumption.
The impact of some anthocyanins and their metabolites on platelet
activation has been previously evaluated. Few studies revealed the in-
ability of lower concentrations (0.5 μM and 1 μM) of cy-3-glc to mod-
ulate P-selectin expression on the platelet surface [18,27,30], which is
line with a lack of the effect of 0.1 μM cy-3-glc observed in our study.
Song et al. and Yang et al. reported that a pretreatment of human
platelet rich plasma or gel-filtered platelets with del-3-glc decreased P-
selectin and GPIIb-IIIa expressions on activated platelets at 5 μM and
50 μM concentrations but not at 0.5 μM level [18,28]. However, in the
present study we showed the potency of low concentration of del-3-glc
to attenuate platelet activation by affecting the expression of P-selectin.
The observed inconsistency could be a result of differences in used
methodology. For example, the use of platelet-rich plasma or gel-fil-
tered platelets requires additional manipulation and thus increases the
Fig. 3. Effects of anthocyanins on platelet-leukocyte aggregation evaluated as A) percentage of platelet-neutrophil (PNA) and B) platelet-monocyte aggregates (PMA) in response to
suboptimal levels of ADP. All anthocyanins were tested at 0.1 μM concentrations. The results are presented as percent of a change compared to control (vehicle-treated, ADP-activated
samples). Data are expressed as mean ± SD, n = 7. *p < 0.05, **p < 0.01.
Fig. 4. Impact of anthocyanin metabolites on A) percentage of platelet-neutrophil (PNA) and B) platelet-monocyte aggregates (PMA) in response to suboptimal levels of ADP. The tested
concentrations were as follows: 0.5 μM for 4-HBAL, 0.2. μM for PCA, 2 μM for hippuric acid, 1 μM for ferulic acid and 2 μM concentration for vanillic acid. The results are represented as
percent of a change compared to control (vehicle-treated, ADP-activated samples). Data are expressed as mean ± SD, n = 7. **p < 0.01.
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susceptibility of platelets to extracorporeal activation, which can mask
fine modulations of platelet function induced by low physiological le-
vels of tested bioactives. In our study, the use of whole blood flow
cytometry, as a prerequisite for sensitive measurement of all markers of
platelet function, allowed as to significantly diminish the extra-
corporeal platelet activation and therefore obtain in vitro results that are
reliable and attributed exclusively to a direct effect of tested com-
pounds. Additionally, the use of strong agonists (e.g., collagen,
thrombin) or weak agonists at rather high concentrations (e.g., 200 μM
ADP) might explain why other studies observed the effect of del-3-glc
only at the supra-physiological concentrations. We investigated the
potency of anthocyanins and their metabolites to modulate platelet
activation and platelet-leukocyte aggregation, induced by exogenously
added ADP at low concentrations. ADP is a physiological platelet ago-
nist stored in the dense granules of platelets and secreted upon their
activation [42]. Platelet response to low concentrations of ADP has
been reported as predictive parameter for cardiovascular events [43].
Thus, it presents a rational target for the evaluation of cardioprotective
effects of selected compounds.
The impact of hippuric acid and PCA on platelet activation has been
previously described as well [29,30,44]. However, these investigations
were performed using concentrations that were higher than those re-
ported in circulation after the consumption of anthocyanin-rich sources
[33,45]. In a recent study by Baeza et al. the pre-incubation of whole
blood with the 0.01 μM-100 μM concentrations of ferulic acid resulted
in a significant decrease in ADP-induced expression of P-selectin only at
higher tested concentrations (10–100 μM) [31]. Similar to our results,
no effect was observed at 1 μM concentration.
To the best of our knowledge, the effects of anthocyanins cy-3-arab,
pn-3-glc and cy-3-gal, as well as metabolites vanillic acid and 4-HBAL,
on platelet activation have not been previously reported. Furthermore,
this is the first study reporting the effects of anthocyanins and their
metabolites on platelet aggregation with leukocytes, a marker that has
been suggested to be an even more sensitive indicator of in vivo platelet
activation than the surface expression of P-selectin or GPIIb-IIIa [46].
In conclusion, this study showed the ex vivo potency of physiologi-
cally relevant concentrations of circulating anthocyanins and their gut
metabolites to reduce platelet activation and aggregation with leuko-
cytes, the processes deeply involved in the development of athero-
sclerosis and CVD. These findings provide potential proof of cause and
effect relationships for the beneficial effect of the consumption of an-
thocyanin-rich sources on platelet function and mechanisms underlying
their cardiovascular protective effects.
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